文献速递创伤骨科关节外科

英国多中心队列研究:非肿瘤性疾病股骨近端置换的临床结局——非肿瘤性疾病内假体置换(EPRO)研究

A UK multicentre cohort study of clinical outcomes of proximal femoral replacement for nononcological conditions : the EndoProsthetic Replacement for nonOncological conditions (EPRO) study.
PubMed 文献 · Bone Joint J · 2025-06-01

本研究为英国六中心回顾性队列研究,纳入226例患者共230例股骨近端置换(PFR),中位年龄76.0岁,中位随访4.2年。局部并发症率为27%,脱位12%、假体周围感染10%;2年假体生存率78.0%(SE 2.8),生存率在不同手术指征、柄长度或柄构造比(CSR)间无显著差异。作者认为因局部并发症和再手术率高,PFR应视为复杂髋重建的挽救性选择。

要点

  • 局部并发症率27%,最常见为脱位(12%)和假体周围感染(10%)。
  • 再手术率21%,2年假体生存率78.0%(SE 2.8)。
  • 作者认为PFR应作为复杂髋重建的挽救性选择,需对患者充分告知。

核心结论

  • 这是非肿瘤性疾病PFR的最大样本研究;因局部并发症和再手术率高,应将其视为复杂髋重建的挽救性选择,并对患者进行适当告知。

研究设计与样本

  • 英国六中心多中心回顾性队列研究,共230例股骨近端置换(PFR),来自226例患者,中位年龄76.0岁(IQR 66.9至83.7),中位随访4.2年(IQR 1.9至7.2)。

主要发现

  • 局部并发症率为27%(n=62),最常见为脱位(n=27;12%)和假体周围感染(n=22;10%)。
  • 86例患者(37%)需要输血,90例患者(39%)需要重症监护。
  • 127例(55%)患者恢复至基线活动能力,200例(87%)患者恢复至基线居住状态。
  • 六个月全身并发症率为9%(n=21),再手术率为21%(n=48);30天死亡率为2%(n=4),一年死亡率为8%(n=19)。
  • 两年假体生存率为78.0%(SE 2.8),不同手术指征、柄长度或柄构造比(CSR)间生存率无显著差异。

关键数值与推荐

  • 手术指征:假体周围股骨骨折(n=62;27%)、感染性翻修关节置换(n=55;24%)、慢性/失败创伤(n=41;18%)、无菌性翻修关节置换(n=38;17%)、急性创伤(n=33;14%)、复杂初次关节置换(n=1;0.5%)。

临床怎么用

  • 作者认为,由于局部并发症和再手术率高,PFR应被视为复杂髋重建的挽救性选择,并对患者进行适当告知。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This study aims to determine the outcomes of proximal femoral replacement (PFR) for nononcological conditions. METHODS: This was a multicentre retrospective cohort study across six UK centres. The primary outcome was the local complication rate. Secondary outcomes were blood transfusions, critical care requirements, return to baseline mobility and residence status, systemic complications, reoperations, and mortality rates. Implant survival analysis was performed using Kaplan-Meier methodology with local complication as the endpoint, and was compared by surgical indication, stem length, and construct stem ratio (CSR). RESULTS: There were 230 PFRs in 226 patients with a median age of 76.0 years (IQR 66.9 to 83.7). Indications were periprosthetic femoral fracture (n = 62; 27%), infected revision arthroplasty (n = 55; 24%), chronic/failed trauma (n = 41; 18%), aseptic revision arthroplasty (n = 38; 17%), acute trauma (n = 33; 14%), and complex primary arthroplasty (n = 1; 0.5%). Median follow-up was 4.2 years (IQR 1.9 to 7.2). The local complication rate was 27% (n = 62). The most common local complications were dislocation (n = 27; 12%) and periprosthetic joint infection (n = 22; 10%). Blood transfusion was required in 86 patients (37%). Overall, 90 patients (39%) required critical care facilities. A return to baseline mobility and residence was observed in 127 (55%) and 200 (87%) patients, respectively. The six-month systemic complication rate was 9% (n = 21) and the reoperation rate was 21% (n = 48). The 30-day and one-year mortality rates were 2% (n = 4) and 8% (n = 19), respectively. The two-year implant survival rate was 78.0% (SE 2.8). Survival rates did not differ significantly by surgical indication, stem length, or CSR. CONCLUSION: This is the largest study of PFR for nononcological conditions. Due to high local complication and reoperation rates, it should be considered a salvage option for complex hip reconstruction and patients should be counselled appropriately.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Wijesekera MP, Pandit H, Palan J, et al. A UK multicentre cohort study of clinical outcomes of proximal femoral replacement for nononcological conditions : the EndoProsthetic Replacement for nonOncological conditions (EPRO) study. Bone Joint J. 2025. PMID: 40449936. doi:10.1302/0301-620X.107B6.BJJ-2024-1304.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。